The latest updates on MS treatments and products.
Aug 29, 2013
The U.S. Food and Drug Administration (FDA) is investigating a case of PML (progressive multifocal leukoencephalopathy, a viral infection of the brain that usually leads to death or severe disability) that occurred in a person taking Gilenya® (fingolimod, Novartis AG). This person had not previously received Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals); read more about the increased risk of PML in people taking Tysabri here, http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=2308). It is not yet known what caused the occurrence of PML in this case.
Mar 27, 2013
The FDA has approved Tecfidera™ capsules (dimethyl fumarate, Biogen Idec –formerly “BG-12”) as a first-line disease-modifying therapy for people with relapsing forms of MS. This makes the third oral therapy approved for relapsing MS, and the tenth disease-modifying treatment available in the U.S. Tecfidera is expected to be available by prescription within a few days.